News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
387,604 Results
Type
Article (26615)
Company Profile (100)
Press Release (360889)
Multimedia
Podcasts (26)
Webinars (7)
Section
Business (105720)
Career Advice (561)
Deals (17227)
Drug Delivery (54)
Drug Development (47915)
Employer Resources (48)
FDA (12324)
Job Trends (8652)
News (188349)
Policy (19758)
Tag
Academia (1781)
Accelerated approval (3)
Adcomms (10)
Allergies (74)
Alliances (27138)
ALS (58)
Alzheimer's disease (824)
Antibody-drug conjugate (ADC) (52)
Approvals (12381)
Artificial intelligence (173)
Autoimmune disease (11)
Automation (4)
Bankruptcy (147)
Best Places to Work (7017)
BIOSECURE Act (6)
Biosimilars (39)
Biotechnology (68)
Bladder cancer (59)
Brain cancer (17)
Breast cancer (193)
Cancer (1449)
Cardiovascular disease (122)
Career advice (504)
Career pathing (13)
CAR-T (71)
Cell therapy (206)
Cervical cancer (13)
Clinical research (40707)
Collaboration (448)
Compensation (126)
Complete response letters (11)
COVID-19 (1521)
CRISPR (14)
C-suite (140)
Cystic fibrosis (50)
Data (1534)
Decentralized trials (2)
Denatured (17)
Depression (32)
Diabetes (176)
Diagnostics (3566)
Digital health (11)
Diversity (5)
Diversity, equity & inclusion (13)
Drug discovery (56)
Drug pricing (54)
Drug shortages (21)
Duchenne muscular dystrophy (56)
Earnings (37264)
Editorial (22)
Employer branding (6)
Employer resources (45)
Events (52611)
Executive appointments (456)
FDA (13317)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (3)
Frontotemporal dementia (3)
Funding (409)
Gene editing (38)
Generative AI (10)
Gene therapy (134)
GLP-1 (408)
Government (3113)
Grass and pollen (3)
Guidances (44)
Healthcare (12351)
Huntington's disease (13)
IgA nephropathy (16)
Immunology and inflammation (42)
Indications (19)
Infectious disease (1593)
Inflammatory bowel disease (79)
Inflation Reduction Act (4)
Influenza (26)
Intellectual property (50)
Interviews (62)
IPO (7187)
IRA (19)
Job creations (1935)
Job search strategy (457)
Kidney cancer (7)
Labor market (12)
Layoffs (182)
Leadership (6)
Legal (3708)
Liver cancer (57)
Lung cancer (233)
Lymphoma (101)
Machine learning (3)
Management (18)
Manufacturing (114)
MASH (48)
Medical device (12948)
Medtech (12951)
Mergers & acquisitions (10338)
Metabolic disorders (439)
Multiple sclerosis (54)
NASH (13)
Neurodegenerative disease (51)
Neuropsychiatric disorders (9)
Neuroscience (1164)
NextGen: Class of 2025 (4018)
Non-profit (2929)
Now hiring (16)
Obesity (222)
Opinion (85)
Ovarian cancer (54)
Pain (66)
Pancreatic cancer (54)
Parkinson's disease (88)
Partnered (11)
Patents (113)
Patient recruitment (82)
Peanut (38)
People (35111)
Pharmaceutical (27)
Pharmacy benefit managers (11)
Phase I (11655)
Phase II (17639)
Phase III (14494)
Pipeline (703)
Policy (61)
Postmarket research (1672)
Preclinical (3657)
Press Release (19)
Prostate cancer (76)
Psychedelics (17)
Radiopharmaceuticals (160)
Rare diseases (198)
Real estate (3079)
Recruiting (17)
Regulatory (14414)
Reports (16)
Research institute (1634)
Resumes & cover letters (60)
Rett syndrome (3)
RNA editing (2)
RSV (23)
Schizophrenia (53)
Series A (66)
Series B (48)
Service/supplier (5)
Sickle cell disease (22)
Special edition (3)
Spinal muscular atrophy (102)
Sponsored (14)
Startups (2162)
Stomach cancer (9)
Supply chain (38)
Tariffs (11)
The Weekly (9)
Vaccines (370)
Venture capitalists (15)
Weight loss (145)
Women's health (17)
Worklife (5)
Date
Today (59)
Last 7 days (469)
Last 30 days (1427)
Last 365 days (18786)
2025 (6000)
2024 (20196)
2023 (23099)
2022 (31037)
2021 (33373)
2020 (32599)
2019 (28967)
2018 (22289)
2017 (19136)
2016 (18405)
2015 (21489)
2014 (16273)
2013 (13542)
2012 (14620)
2011 (14982)
2010 (13405)
Location
Africa (388)
Alabama (17)
Alaska (2)
Arizona (120)
Arkansas (11)
Asia (25023)
Australia (3965)
California (3108)
Canada (1236)
China (375)
Colorado (167)
Connecticut (178)
Delaware (117)
Europe (48963)
Florida (549)
Georgia (129)
Idaho (33)
Illinois (361)
India (15)
Indiana (225)
Iowa (3)
Japan (119)
Kansas (75)
Kentucky (12)
Louisiana (7)
Maine (27)
Maryland (643)
Massachusetts (2178)
Michigan (148)
Minnesota (272)
Mississippi (2)
Missouri (53)
Montana (18)
Nebraska (18)
Nevada (33)
New Hampshire (60)
New Jersey (1130)
New Mexico (10)
New York (974)
North Carolina (557)
North Dakota (4)
Northern California (1353)
Ohio (134)
Oklahoma (3)
Oregon (24)
Pennsylvania (829)
Puerto Rico (7)
Rhode Island (24)
South America (554)
South Carolina (21)
Southern California (1175)
Tennessee (79)
Texas (546)
United States (13002)
Utah (112)
Virginia (81)
Washington D.C. (39)
Washington State (235)
West Virginia (3)
Wisconsin (44)
387,604 Results for "silk road medical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Boston Scientific Announces Agreement to Acquire Silk Road Medical, Inc.
Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Silk Road Medical, Inc.
June 18, 2024
·
7 min read
Deals
Silk Road Medical Announces Definitive Agreement to be Acquired by Boston Scientific
Silk Road Medical, Inc. announced it has entered into a definitive agreement to be acquired by Boston Scientific Corporation, a global medical technology leader, for $27.50 in cash per share, representing an equity value of approximately $1.26 billion.
June 18, 2024
·
7 min read
Business
Silk Road Medical Reports First Quarter 2024 Financial Results
Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended March 31, 2024.
April 30, 2024
·
8 min read
Biotech Bay
Silk Road Medical to Present at the BofA Securities 2024 Healthcare Conference
Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will participate in the upcoming BofA Securities 2024 Healthcare Conference.
April 23, 2024
·
1 min read
Business
Silk Road Medical to Report First Quarter 2024 Financial Results on April 30, 2024
Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, April 30th, 2024.
April 9, 2024
·
1 min read
Biotech Bay
Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Transcarotid Neuroprotection System PLUS
Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the launch of its ENROUTE® Transcarotid Neuroprotection System PLUS (“NPS PLUS”), a key component of the TCAR® portfolio.
April 2, 2024
·
3 min read
Biotech Bay
Silk Road Medical Expands TCAR® Portfolio with Launch of Tapered ENROUTE® Transcarotid Stent System
Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that it has launched its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States.
March 5, 2024
·
3 min read
Press Releases
Boston Scientific Closes Acquisition of Silk Road Medical, Inc.
September 17, 2024
·
5 min read
Business
Silk Road Medical Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Financial Outlook
Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months and full year ended December 31, 2023.
February 28, 2024
·
10 min read
Business
Silk Road Medical to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Wednesday, February 28th, 2024.
February 7, 2024
·
1 min read
1 of 38,761
Next
